Style | Citing Format |
---|---|
MLA | Obrart D, et al.. "Comment On: “What Are the Costs, Capacity, and Clinical Implications of “Waiting for Documented Progression” in Young West of Scotland Patients Prior to Collagen Cross Linking?”." Eye (Basingstoke), vol. 36, no. 7, 2022, pp. 1512-. |
APA | Obrart D, Zareighanavati M, Vasquezperez A, Liu C (2022). Comment On: “What Are the Costs, Capacity, and Clinical Implications of “Waiting for Documented Progression” in Young West of Scotland Patients Prior to Collagen Cross Linking?”. Eye (Basingstoke), 36(7), 1512-. |
Chicago | Obrart D, Zareighanavati M, Vasquezperez A, Liu C. "Comment On: “What Are the Costs, Capacity, and Clinical Implications of “Waiting for Documented Progression” in Young West of Scotland Patients Prior to Collagen Cross Linking?”." Eye (Basingstoke) 36, no. 7 (2022): 1512-. |
Harvard | Obrart D et al. (2022) 'Comment On: “What Are the Costs, Capacity, and Clinical Implications of “Waiting for Documented Progression” in Young West of Scotland Patients Prior to Collagen Cross Linking?”', Eye (Basingstoke), 36(7), pp. 1512-. |
Vancouver | Obrart D, Zareighanavati M, Vasquezperez A, Liu C. Comment On: “What Are the Costs, Capacity, and Clinical Implications of “Waiting for Documented Progression” in Young West of Scotland Patients Prior to Collagen Cross Linking?”. Eye (Basingstoke). 2022;36(7):1512-. |
BibTex | @article{ author = {Obrart D and Zareighanavati M and Vasquezperez A and Liu C}, title = {Comment On: “What Are the Costs, Capacity, and Clinical Implications of “Waiting for Documented Progression” in Young West of Scotland Patients Prior to Collagen Cross Linking?”}, journal = {Eye (Basingstoke)}, volume = {36}, number = {7}, pages = {1512-}, year = {2022} } |
RIS | TY - JOUR AU - Obrart D AU - Zareighanavati M AU - Vasquezperez A AU - Liu C TI - Comment On: “What Are the Costs, Capacity, and Clinical Implications of “Waiting for Documented Progression” in Young West of Scotland Patients Prior to Collagen Cross Linking?” JO - Eye (Basingstoke) VL - 36 IS - 7 SP - 1512 EP - PY - 2022 ER - |